20856911|t|Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).
20856911|a|Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal motor symptoms: resting tremor, rigidity, and bradykinesia. Since its introduction 40 years ago, levodopa has represented the gold standard for dopaminergic stimulation therapy in patients with PD. Levodopa is routinely combined with a dopa-decarboxylase inhibitor (DDCI) to prevent the conversion of levodopa into dopamine in peripheral circulation. However, up to 80% of patients treated with continuous levodopa manifest the onset of disabling motor complications capable of producing an adverse effect on quality of life as the disease progresses. In recent years, a new, safe, and efficacious armamentarium of treatment options has been provided by the marketing of the catechol-O-methyltransferase (COMT) inhibitor, entacapone, a peripheral blocker of dopa to 3-0-methyldopa metabolism, which increments levodopa brain availability. When administered with levodopa, entacapone conjugates the rapid onset of levodopa-induced effects with a protracted efficiency, thus providing additional benefits to classic levodopa treatment by increasing "on" time in fluctuating PD patients, and theoretically providing a more continuous and physiological-like stimulation of dopamine receptors implying a reduced risk of motor complications. In this context, the use of a single administration of combined carbidopa/ levodopa/entacapone (Stalevo( )) in the treatment of PD affords clinical improvements similar to those obtained by 2 separate tablets (ie, levodopa/DDCI and entacapone), although the former produces a more positive effect on quality of life than the latter. Additionally, the STalevo Reduction In Dyskinesia Evaluation (STRIDE-PD) study was designed with the aim of demonstrating that the combination of levodopa, carbidopa, and entacapone, used as initial levodopa therapy, significantly delays the onset of dyskinesias compared with the conventional levodopa/carbidopa formulation. Unfortunately, STRIDEPD failed to prove the benefit of continuous dopaminergic stimulation with triple therapy in a clinical setting. Recently, the effect of combined COMT inhibitor with levodopa administration in reducing homocysteine synthesis has been described. To this regard, clear evidence has been presented indicating homocysteine as a risk factor for vascular diseases, cognitive impairment, and dementia. Several studies have discussed the potential of entacapone as adjunct to levodopa/ DDCI in reducing plasma homocysteine levels with contrasting results.
20856911	63	80	Parkinson disease	Disease	MESH:D010300
20856911	99	128	carbidopa/levodopa/entacapone	Chemical	-
20856911	130	137	Stalevo	Chemical	MESH:C481098
20856911	140	157	Parkinson disease	Disease	MESH:D010300
20856911	159	161	PD	Disease	MESH:D010300
20856911	168	194	neurodegenerative disorder	Disease	MESH:D019636
20856911	239	253	resting tremor	Disease	MESH:D014202
20856911	255	263	rigidity	Disease	MESH:D009127
20856911	269	281	bradykinesia	Disease	MESH:D018476
20856911	320	328	levodopa	Chemical	MESH:D007980
20856911	367	379	dopaminergic	Chemical	MESH:D004298
20856911	403	411	patients	Species	9606
20856911	417	419	PD	Disease	MESH:D010300
20856911	421	429	Levodopa	Chemical	MESH:D007980
20856911	524	532	levodopa	Chemical	MESH:D007980
20856911	538	546	dopamine	Chemical	MESH:D004298
20856911	596	604	patients	Species	9606
20856911	629	637	levodopa	Chemical	MESH:D007980
20856911	898	926	catechol-O-methyltransferase	Gene	1312
20856911	928	932	COMT	Gene	1312
20856911	945	955	entacapone	Chemical	MESH:C071192
20856911	981	985	dopa	Chemical	MESH:D004295
20856911	989	1003	3-0-methyldopa	Chemical	-
20856911	1033	1041	levodopa	Chemical	MESH:D007980
20856911	1085	1093	levodopa	Chemical	MESH:D007980
20856911	1095	1105	entacapone	Chemical	MESH:C071192
20856911	1136	1144	levodopa	Chemical	MESH:D007980
20856911	1237	1245	levodopa	Chemical	MESH:D007980
20856911	1295	1297	PD	Disease	MESH:D010300
20856911	1298	1306	patients	Species	9606
20856911	1523	1532	carbidopa	Chemical	MESH:D002230
20856911	1534	1542	levodopa	Chemical	MESH:D007980
20856911	1543	1553	entacapone	Chemical	MESH:C071192
20856911	1555	1562	Stalevo	Chemical	MESH:C481098
20856911	1587	1589	PD	Disease	MESH:D010300
20856911	1673	1681	levodopa	Chemical	MESH:D007980
20856911	1691	1701	entacapone	Chemical	MESH:C071192
20856911	1810	1817	STalevo	Chemical	MESH:C481098
20856911	1831	1841	Dyskinesia	Disease	MESH:D004409
20856911	1861	1863	PD	Disease	MESH:D010300
20856911	1938	1946	levodopa	Chemical	MESH:D007980
20856911	1948	1957	carbidopa	Chemical	MESH:D002230
20856911	1963	1973	entacapone	Chemical	MESH:C071192
20856911	1991	1999	levodopa	Chemical	MESH:D007980
20856911	2043	2054	dyskinesias	Disease	MESH:D004409
20856911	2086	2104	levodopa/carbidopa	Chemical	MESH:C009265
20856911	2184	2196	dopaminergic	Chemical	MESH:D004298
20856911	2305	2313	levodopa	Chemical	MESH:D007980
20856911	2341	2353	homocysteine	Chemical	MESH:D006710
20856911	2445	2457	homocysteine	Chemical	MESH:D006710
20856911	2479	2496	vascular diseases	Disease	MESH:D014652
20856911	2498	2518	cognitive impairment	Disease	MESH:D003072
20856911	2524	2532	dementia	Disease	MESH:D003704
20856911	2582	2592	entacapone	Chemical	MESH:C071192
20856911	2607	2615	levodopa	Chemical	MESH:D007980
20856911	2641	2653	homocysteine	Chemical	MESH:D006710
20856911	Negative_Correlation	MESH:C071192	MESH:D004409
20856911	Comparison	MESH:C009265	MESH:C071192
20856911	Cotreatment	MESH:C071192	MESH:C481098
20856911	Negative_Correlation	MESH:C071192	MESH:D004295
20856911	Negative_Correlation	MESH:C071192	1312
20856911	Negative_Correlation	MESH:C071192	MESH:D010300
20856911	Cotreatment	MESH:D002230	MESH:D007980
20856911	Cotreatment	MESH:C071192	MESH:D002230
20856911	Positive_Correlation	MESH:D006710	MESH:D014652
20856911	Positive_Correlation	MESH:C071192	MESH:D003072
20856911	Negative_Correlation	MESH:D002230	MESH:D010300
20856911	Negative_Correlation	MESH:D002230	MESH:D004409
20856911	Negative_Correlation	MESH:D007980	MESH:D010300
20856911	Negative_Correlation	MESH:D007980	MESH:D018476
20856911	Positive_Correlation	MESH:D006710	MESH:D003704
20856911	Comparison	MESH:C009265	MESH:D007980
20856911	Association	MESH:D007980	MESH:D004409
20856911	Cotreatment	MESH:C481098	MESH:D007980
20856911	Cotreatment	MESH:C071192	MESH:D007980
20856911	Negative_Correlation	MESH:C481098	MESH:D010300
20856911	Cotreatment	MESH:D004298	MESH:D007980
20856911	Negative_Correlation	MESH:C481098	MESH:D004409
20856911	Positive_Correlation	MESH:D006710	MESH:D003072

